<DOC>
	<DOCNO>NCT03066453</DOCNO>
	<brief_summary>The aim study investigate efficacy antibiotic therapy antibiotic ( IV ) IV ( Nebcin® ) tobramycin 5 day follow Solution nebuliser inhalation ( Tobi® ) 9 day antibiotic cure use 14 day tobramycin IV . In case positive result , reduction duration IV treatment tobramycin 14 day 5 day would limit risk toxicity .</brief_summary>
	<brief_title>Evaluation Short Antibiotic Combination Courses Followed Aerosols Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>Patient cystic fibrosis confirm sweat genetic test Patient clinical sign exacerbation ( increased cough , sputum ( abundance , purulence ) , fever , anorexia , weight loss FEV1 ) acute exacerbation ( defined clinician 's discretion ) FEV1 ≥ 25 % Pseudomonas aeruginosa chronic carrier ( define least two antipyocyanic precipitation arc least 3 successive positive ECBCs period 18 month ) Patient receive least 1 IV course antibiotic year prior inclusion . Severe exacerbation ( require hospitalization due severe amputation FEV 1 , oxygen deficiency , severe impairment general health ) . Patient colonize Burkholderia cepacia Patient colonize atypical mycobacterium Patient pulmonary transplant transplant Hypersensitivity tobramycin antibiotic aminoglycoside family Cirrhosis Grades B C accord ChildPugh Classification Myasthenia gravis Simultaneous administration another aminoglycoside Renal failure Recent history severe hemoptysis ( within 2 month inclusion ) Antibiotic treatment prescribe systematic manner Patient participate simultaneously another clinical study conduct drug duration participation research</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cystic fibrosis , tobramycin , antibiotic course , FEV1</keyword>
</DOC>